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Abstract
APOBEC3G is a cytidine deaminase with potent antiviral activity. The protein deaminates single-
stranded DNA but is known to bind cellular and viral RNAs. There is increasing evidence that RNA
binding of APOBEC3G is important for packaging into viral particles. However, there is no
consensus yet on the type of RNA involved.
Commentary
APOBEC3G is a cytidine deaminase that was recently
identified as the prime substrate of the HIV-1 viral infec-
tivity factor Vif [1]. In the absence of Vif, APOBEC3G is
packaged into viral cores and potently interferes with virus
replication (for a recent review see [2]). While it is undis-
puted that much of APOBEC3G's antiviral activity comes
from its encapsidation into virions, the mechanism of
APOBEC3G packaging remains under discussion. Several
studies conclude that APOBEC3G packaging is RNA inde-
pendent and mediated by an APOBEC3G:Gag interaction
while others identified a requirement for viral or cellular
RNA in the APOBEC3G packaging process (Figure 1).
The study by Bach et al. [3] attempts to shed light onto the
mechanism of APOBEC3G packaging. As far as the
requirement of NC for packaging of 7SL RNA is con-
cerned, the authors' data are in good agreement with a
previous report by Wang et al. [4] showing that deletion
of NC reduced packaging of 7SL RNA. Bach et al. disagree,
however, with two other reports who found no significant
NC-dependence for 7SL packaging [5,6]. Thus, the vote is
tied at 2:2 on this issue. As far as the requirement of 7SL
RNA for the packaging of APOBEC3G is concerned, Bach
et al. fail to observe a correlation between APOBEC3G
packaging and 7SL RNA incorporation. They therefore
side with Khan et al. who previously also failed to see such
a correlation [6]. Thus, the score is 2:1 against an involve-
ment of 7SL RNA in the packaging of APOBEC3G. Unfor-
tunately, Bach et al. did not analyze the importance of
genomic RNA for APOBEC3G packaging, an issue on
which Wang and Khan disagree. The score on that issue
therefore remains tied at 1:1. Svarovskaia et al. also
remain neutral on this issue by proposing that incorpora-
tion of APOBEC3G into HIV-1 virions involves both viral
and nonviral RNAs [7].
There clearly is a trend in the field to accept the impor-
tance of RNA in the packaging of APOBEC3G into HIV-1
virions. But which RNA is it? There is no simple answer to
this conundrum. Bach et al. point out that they and Wang
et al. use a highly quantitative assay for determining
encapsidation of 7SL RNA. So part of the difference may
be attributed to differences in sensitivity. Some of the con-
fusion may also come from the use of different experi-
mental model systems, i.e. virus-like particles (VLP)
versus whole virus. Also, it often is not appreciated that
packaging of APOBEC3G into HIV virions or VLPs is as
much a qualitative as it is a quantitative problem. For
instance, the cytidine deaminase APOBEC3A is packaged
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into HIV virions but does not associate with viral cores
and has no antiviral activity [8]. However, when the pro-
tein is artificially targeted to viral cores, APOBEC3A does
develop antiviral properties [8,9]. Thus investigating
APOBEC3G packaging into VLP rather than intact virions
may allow the investigation of the quantitative aspect of
APOBEC3G packaging but may fail to consider the quali-
tative aspect. Finally, protein overexpression is becoming
an increasing concern in the APOBEC field. Some of the
discrepant results on the role of RNA in the packaging of
APOBEC3G into HIV-1 virions could potentially be
explained by relative differences in protein expression.
In conclusion, the final verdict on what RNA guides the
packaging of APOBEC3G into HIV-1 virions is still out
and awaits further investigation. In particular, it remains
to be determined whether APOBEC3G encapsidation
entails a specific (e.g. viral RNA) and/or a non-specific
component (e.g. cellular RNA). However, it is our (not
completely unbiased) opinion that viral genomic RNA is
excellently placed to make the finals.
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Mechanism of APOBEC3G encapsidation Figure 1
Mechanism of APOBEC3G encapsidation. Four differ-
ent scenarios can be envisioned: (1) APOBEC3G is packaged 
non-specifically. This possibility seems unlikely given the 
known affinity of APOBEC3G to viral Gag proteins and viral 
and cellular RNAs. (2) APOBEC3G is packaged through 
interaction with Gag in an RNA-independent manner. Such a 
mechanism was initially proposed as discussed in the text. (3) 
APOBEC3G interacts with host RNA; in particular 7SL RNA 
was proposed to mediate encapsidation of APOBEC3G. (4) 
APOBEC3G is packaged through specific interaction with 
viral genomic RNA. This model is our favorite and is sup-
ported by the observation that point mutations in the 5' 
untranslated region of the viral genome can severely affect 
APOBEC3G packaging without affecting 7SL RNA encapsida-
tion [6,10]. This model is also consistent with the data 
reported by Bach et al. [3].